5、消化系统肿瘤消化系统肿瘤 (8).pdf
《5、消化系统肿瘤消化系统肿瘤 (8).pdf》由会员分享,可在线阅读,更多相关《5、消化系统肿瘤消化系统肿瘤 (8).pdf(5页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。
1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 3_suppl Meeting Abstract|2021 Gastrointestinal Cancers SymposiumHEPATOBILIARY CANCERFinal results from a phase II study ofinfigratinib(BGJ398),an FGFR-selectivetyrosine kinase inhibitor,in patients withpreviously treated advancedRights&Per
2、missionsOPTIONS&TOOLSExport CitationTrack CitationAdd To FavoritesCOMPANION ARTICLESADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article Toolscholangiocarcinoma harboring an FGFR2gene fusion or rearrangement.Milind M.Javle,Sameek Roychowdhury,Robin Kate Kelley,Saeed
3、 Sadeghi,Teresa Macarulla,Dirk Thomas Waldschmidt,.Show MoreAbstract Disclosures265Background:Treatment options forcholangiocarcinoma(CCA)after progression onfirst-line gemcitabine-based therapy are limited.Fibroblast growth factor receptor 2(FGFR2)genefusions occur in 1317%of intrahepatic CCA.Asing
4、le-arm,phase II study(NCT02150967)evaluated infigratinib,an ATP-competitive FGFR13-selective oral tyrosine kinase inhibitor,inpreviously-treated advanced CCA with FGFRfusions/rearrangements.Methods:Adult patientswith advanced/metastatic CCA with progressionNo companion articlesARTICLE CITATIONDOI:10
5、.1200/JCO.2021.39.3_suppl.265Journal of Clinical Oncology 39,no.3_suppl(January 20,2021)265-265.Published online January 22,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of C
6、hicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package
7、,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractFinal Phase II Data SupportInfigratinib in Chemotherapy-refractory CholangiocarcinomaHarboring FGFR2 Fusi
8、onsASCO Daily News,2021Phase II Study of BGJ398 in PatientsWith FGFR-Altered AdvancedCholangiocarcinomaMilind Javle et al.,J Clin Oncol,2017FGFR Kinase Inhibitor in FGFR-Altered AdvancedCholangiocarcinomaBy Matthew Stenger et al.,Hepatobiliary CancerLack of Targetable FGFR2 Fusions inEndemic Fluke-A
9、ssociatedCholangiocarcinomaSarinya Kongpetch et al.,JCO GlobalOncology,2020Cholangiocarcinoma With FGFRGenetic Aberrations:A UniqueClinical Phenotypeon 1 line of systemic therapy received infigratinib125 mg orally for 21 days of each 28-day cycle untilunacceptable toxicity or disease progression.All
10、patients received prophylaxis with the oralphosphate binder sevelamer.Primary endpoint:objective response rate(ORR)by independentcentral review per RECIST v1.1,with duration ofresponse(DOR).Secondary endpoints:progression-free survival(PFS),disease controlrate,overall survival,safety,pharmacokinetic
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 5、消化系统肿瘤消化系统肿瘤 8 消化系统 肿瘤
限制150内